Abliva
0,168 SEK +2,07%Vær den første som følger denne virksomhed
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Omsætning
140 t
EBIT %
-68.964,29 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ABLI
Daglig lav / høj pris
0,164 / 0,17
SEK
Markedsværdi
270,8 mio. SEK
Aktieomsætning
130,68 t SEK
Volumen
783 t
Seneste videoer
Finanskalender
Delårsrapport
21.11.2024
Årsrapport
21.02.2025
Delårsrapport
22.05.2025
Delårsrapport
22.08.2025
Delårsrapport
21.11.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Hadean Capital I AS | 22,4 % | 22,4 % |
Oslo Pensjonsforsikring AS | 14,9 % | 14,9 % |
IP Group Plc | 8,1 % | 8,1 % |
Försäkringsaktiebolaget, Avanza Pension | 3,3 % | 3,3 % |
Christen Sveaas | 2,7 % | 2,7 % |
MP Pensjon PK | 2,7 % | 2,7 % |
Kistefos AS | 2,1 % | 2,1 % |
Liljenberg, Stefan | 1,5 % | 1,5 % |
Nordnet Pension insurance | 1,1 % | 1,1 % |
Johan Thorell | 0,8 % | 0,8 % |
Swedbank Insurance | 0,6 % | 0,6 % |
Johan Bard | 0,6 % | 0,6 % |
Gunvald Berger | 0,6 % | 0,6 % |
ViserAlle indholdstyper
Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
Amended number of shares and votes in Abliva AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools